Paper · 42875645

A review on MMP-2 modulating agents from natural and synthetic sources and their role in inflammatory bowel disease.

Ragunath M and 3 others. Inflammopharmacology, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. A review on MMP-2 modulating agents from natural and synthetic sources and their role in inflammatory bowel disease. Papers, record 42875645. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42875645

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: A review on MMP-2 modulating agents from natural and synthetic sources and their role in inflammatory bowel disease.
Journal: Inflammopharmacology
Year: 2026
Publication types: Journal Article, Review
PubMed: https://pubmed.ncbi.nlm.nih.gov/42875645/
DOI: https://doi.org/10.1007/s10787-026-02427-8
The journal: https://conductscience.org/library/journal-index/9112626
Revised in PubMed: 2026-10-14

Source PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Ragunath M	Murugasamy
2	Ardra S	Sudarsan
3	Balde A	Akshad
4	Nazeer RA	Rasool Abdul	https://orcid.org/0000-0002-0587-3770

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References111

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	27,452,283	Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.	Bioorg Med Chem	2016	https://conductscience.org/library/papers/27452283	PubMed
2	39,233,391	Biphenylsulfonamides as effective MMP-2 inhibitors with promising antileukemic efficacy: Synthesis, in vitro biological evaluation, molecular docking, and MD simulation analysis.	Drug Dev Res	2024	https://conductscience.org/library/papers/39233391	PubMed
3	23,300,643	IL-13 promotes collagen accumulation in Crohn's disease fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate lymphoid cells?	PLoS One	2012	https://conductscience.org/library/papers/23300643	PubMed
4	12,235,282	Metalloproteinase inhibitors: biological actions and therapeutic opportunities.	J Cell Sci	2002	https://conductscience.org/library/papers/12235282	PubMed
5	37,982,191	An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present).	Expert Opin Ther Pat	2023	https://conductscience.org/library/papers/37982191	PubMed
6	19,766,083	Regulatory T cells reinforce intestinal homeostasis.	Immunity	2009	https://conductscience.org/library/papers/19766083	PubMed
7	28,394,608	Second Generation Triple-Helical Peptide Inhibitors of Matrix Metalloproteinases.	J Med Chem	2017	https://conductscience.org/library/papers/28394608	PubMed
8	19,111,728	Is inflammatory bowel disease a vascular disease? Targeting angiogenesis improves chronic inflammation in inflammatory bowel disease.	Gastroenterology	2009	https://conductscience.org/library/papers/19111728	PubMed
9	41,069,169	Recent advances in the design and development of small-molecule MMP-2 inhibitors.	Future Med Chem	2025	https://conductscience.org/library/papers/41069169	PubMed
10	25,415,508	Remodelling the extracellular matrix in development and disease.	Nat Rev Mol Cell Biol	2014	https://conductscience.org/library/papers/25415508	PubMed

1 to 10 of 111

See all 111 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42875645

GET https://conductscience.org/api/papers/v1/42875645/references?page=2

API reference For AI assistants